Athenex, Inc. (ATNX)
| Market Cap | 109.32M |
| Revenue (ttm) | 117.05M |
| Net Income (ttm) | -144.87M |
| Shares Out | 109.32M |
| EPS (ttm) | -1.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 897,335 |
| Open | 1.05 |
| Previous Close | 1.06 |
| Day's Range | 1.00 - 1.06 |
| 52-Week Range | 1.00 - 15.00 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 7.50 (+650.0%) |
| Earnings Date | n/a |
About ATNX
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer d...
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for Athenex stock is "Buy." The 12-month stock price forecast is 7.50, which is an increase of 650.00% from the latest price.
News
Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility
BUFFALO, N.Y., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...
SHAREHOLDER ALERT: Robbins LLP is Investigating Athenex, Inc. (ATNX) for Shareholders
SAN DIEGO, Calif. & BUFFALO, N.Y.--(BUSINESS WIRE)---- $ATNX #breastcancer--Athenex, Inc. (ATNX) Misstated the Efficacy of its Lead Drug Candidate and the Likelihood the FDA Would Approve its New Drug A...
Athenex to Host a KOL Webinar Today on CAR-NKT Cell Approach to Cancer and Latest Data at the 63rd ASH Annual Meeting
The Company will host a virtual Key Opinion Leader event today at 9:00 a.m. ET to discuss its CAR-NKT cell therapy platform
Athenex Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar fo...
BUFFALO, N.Y., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...
Athenex To Present Subgroup Analysis Of Oral Paclitaxel-Encequidar Combo Data From Breast Cancer Trial
Athenex Inc's (NASDAQ: ATNX) abstract for subgroup analysis of its Phase 3 study of oral paclitaxel and encequidar (Oral Paclitaxel) for metastatic breast cancer has been accepted for poster presentatio...
Are Options Traders Betting on a Big Move in Athenex (ATNX) Stock?
Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.
Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference
BUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...
Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mu...
Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs to target solid tumors Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs...
Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates
Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and 66.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory ...
Results from five patients showed best responses of 2 partial responses (PR), 1 complete response with incomplete hematological recovery (CRi) and 1 complete response (CR).
Athenex (ATNX) Sees Hammer Chart Pattern: Time to Buy?
Athenex (ATNX) has been struggling lately, but the selling pressure may be coming to an end soon.
Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021
BUFFALO, N.Y., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the trea...
Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 5, 2021
BUFFALO, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the trea...
Athenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Ce...
Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR)
After Plunging 25.6% in 4 Weeks, Here's Why the Trend Might Reverse for Athenex (ATNX)
Athenex (ATNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates cou...
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer
BUFFALO, N.Y., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the trea...
5 Penny Stocks To Buy According To Insiders In September
Insiders are buying shares of these penny stocks this months; are you? The post 5 Penny Stocks To Buy According To Insiders In September appeared first on Penny Stocks to Buy, Picks, News and Informatio...
Athenex Shares Are Trading Higher On Positive Oral Paclitaxel Data From Solid Tumor Trial
Athenex Inc (NASDAQ: ATNX) announced data presentation from a Phase 1 study evaluating encequidar (Oral Paclitaxel) in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in advanced so...
Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021
Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging anti-tumor activity (4 PR out of 8 evaluable patients) in NSCLC patients who failed prior PD1/PDL1 therapies Sa...
Athenex to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & Med Tech Summit
BUFFALO, N.Y., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for ...
Athenex (ATNX) Reports Q2 Loss, Misses Revenue Estimates
Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and -0.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Athenex Provides Second Quarter 2021 Corporate and Financial Update
Updated investors on FDA Type A Meeting for oral paclitaxel
Athenex Announces Additional Licensing Agreements for Tirbanibulin
Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada Athenex expands its international commercial partnerships for tirbanibulin in Australia, N...
Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021
BUFFALO, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for th...
Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe
Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.